1. Cannabidiol mitigates radiation-induced intestine ferroptosis via facilitating the heterodimerization of RUNX3 with CBFβ thereby promoting transactivation of GPX4.
- Author
-
Huang C, Zhang L, Shen P, Wu Z, Li G, Huang Y, Ao T, Luo L, Hu C, Wang N, Quzhuo R, Tian L, Huangfu C, Liao Z, and Gao Y
- Subjects
- Humans, Animals, Mice, Intestines radiation effects, Intestines pathology, Protein Multimerization drug effects, NF-kappa B metabolism, NF-kappa B genetics, Cannabidiol pharmacology, Transcriptional Activation drug effects, Ferroptosis drug effects, Ferroptosis genetics, Phospholipid Hydroperoxide Glutathione Peroxidase metabolism, Phospholipid Hydroperoxide Glutathione Peroxidase genetics, Core Binding Factor Alpha 3 Subunit metabolism, Core Binding Factor Alpha 3 Subunit genetics, Core Binding Factor beta Subunit metabolism, Core Binding Factor beta Subunit genetics
- Abstract
Radiation enteritis remains a major challenge for radiotherapy against abdominal and pelvic malignancies. Nevertheless, there is no approved effective therapy to alleviate irradiation (IR)-induced gastrointestinal (GI) toxicity. In the current study, Cannabidiol (CBD) was found to mitigate intestinal injury by GPX4-mediated ferroptosis resistance upon IR exposure. RNA-sequencing was employed to investigate the underlying mechanism involved in the radio-protective effect of CBD, wherein runt-related transcription factor 3 (RUNX3) and its target genes were changed significantly. Further experiment showed that the transactivation of GPX4 triggered by the direct binding of RUNX3 to its promoter region, or by stimulating the transcriptional activity of NF-κB via RUNX3-mediated LILRB3 upregulation was critical for the anti-ferroptotic effect of CBD upon IR injury. Specially, CBD was demonstrated to be a molecular glue skeleton facilitating the heterodimerization of RUNX3 with its transcriptional chaperone core-biding factor β (CBFβ) thereby promoting their nuclear localization and the subsequent transactivation of GPX4 and LILRB3. In short, our study provides an alternative strategy to counteract IR-induced enteritis during the radiotherapy on abdominal/pelvic neoplasms., Competing Interests: Declaration of competing interest The authors declare no conflicts of interest., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF